{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01552",
      "entity_text" : "ipilimumab",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02324",
      "entity_text" : "PD-1L",
      "features" : [ {
        "modification_type" : "unknown",
        "feature_type" : "modification"
      } ],
      "entity_type" : "gene_or_gene_product"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Upregulation of PD-1L expression on tumor cells increases the effect of pembrolizumab.14 Combination of talimogene laherparepvec and ipilimumab has been evaluated in a phase Ib and phase II studies, both showing higher efficacy in combination than as a monotherapy of talimogene laherparepvec or ipilimumab alone.15, 16 Talimogene laherparepvec intralesional injections before pembrolizumab administration promoted the CD8 + cell infiltration into tumor.",
  "reading_complete" : "2020-08-03T11:48:36Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T11:47:50Z",
  "trigger" : "increases",
  "evidence" : [ "PD-1L expression on tumor cells increases the effect of pembrolizumab.14\n\n\nCombination of talimogene laherparepvec and ipilimumab" ],
  "pmc_id" : "6552946",
  "score" : 0
}